TRIO NRSA Training Core

TRIO NRSA 培训核心

基本信息

项目摘要

Today’s incipient and early career trainees in Kidney, Urologic, Hematologic (KUH) fields require training within environments richly populated by accomplished team-science researchers and adept, committed mentors. Trainees must learn sophisticated research tools while simultaneously completing didactic coursework and developing professional development skills. Coordinating these efforts will enable scale-up of high-impact practices to remove the daunting academic and social barriers that have caused persistent disparities among KUH clinicians and researchers, and the direct gains of this training program will be realized most by the KUH patient populations we serve. Training the next generation of KUH researchers requires institutions and mentors to synergistically engage in both research and training. We have brought together KUH researchers at 3 leading North Carolina (NC) biomedical research universities: University of North Carolina-Chapel Hill, Wake Forest University, and Duke University, as well as from 3 Historically Black Colleges and Universities, NC Agricultural & Technical State University, Winston-Salem State University and NC Central University. Together, this forms the NC KUH TRIO (Training, Research, Innovation, Outreach, or TRIO) U2C/TL1 Research Training Program. The TRIO Training Core has 3 objectives: 1) provide didactics and hands-on experience in rigorous basic/translational and clinical sciences research; 2) conduct research that includes adoption of emerging technologies and builds on the cross-disciplinary and cross-institutional team science across the KUH mission; and 3) establishes and nourishes a community of scholars that expands and sustains diversity in KUH research. Multidisciplinary and team research skills will be developed under the Professional Development Core in conjunction with Clinical and Translational Science Award (CTSA) programs. A connected community of TRIO scholars, that spans from high school to early faculty, will be built and supported by the Networking Core. Qualified and motivated TRIO mentors will train both pre- and post-doctoral trainees across broad, highly relevant KUH scientific specialties that span basic/translational, clinical, and technology arenas. Emerging mentors will mature to assure future leadership and longevity of the program. TRIO will exploit existing multi-institutional training infrastructures and programs in biotechnology, public health, translational science, and clinical research. A robust and transparent admissions process with targeted recruitment will foster diversity, and rigorous program evaluation will allow real-time improvement in serving the needs of our KUH trainees. The integrated TRIO program will leverage cross-institutional synergies and provide cohesive programming to train the next generation leaders in multidisciplinary and team KUH-relevant research.
今天的初期和早期职业培训生在肾脏,泌尿,血液(KUH)领域需要培训 在由有成就的团队科学研究人员和熟练的、忠诚的导师组成的环境中。 学员必须学习复杂的研究工具,同时完成教学课程, 发展专业发展技能。协调这些努力将有助于扩大影响力大的 这些障碍造成了学生之间持续的不平等, KUH的临床医生和研究人员,这一培训计划的直接收益将实现KUH最 我们服务的患者群体培养下一代KUH研究人员需要机构和导师 以协同方式参与研究和培训。我们聚集了KUH研究人员在3领先 北卡罗来纳州(NC)生物医学研究型大学:北卡罗来纳大学教堂山分校,维克森林 大学,和杜克大学,以及从3个历史上黑人学院和大学,北卡罗来纳州农业 和技术州立大学,温斯顿-塞勒姆州立大学和北卡罗来纳州中央大学。这就形成了 NC KUH TRIO(培训,研究,创新,推广或TRIO)U2 C/TL 1研究培训计划。 TRIO培训核心有3个目标:1)提供教学和实践经验, 基础/转化和临床科学研究; 2)进行研究,包括采用新兴的 技术,并建立在跨学科和跨机构的团队科学整个KUH使命; 和3)建立和维护一个学者社区,扩大和维持KUH研究的多样性。 多学科和团队研究技能将在专业发展核心下发展, 临床和转化科学奖(CTSA)。TRIO的互联社区 学者,从高中到早期的教师,将建立和网络核心的支持。 合格和积极的TRIO导师将在广泛的,高度的 相关KUH科学专业跨越基础/转化,临床和技术领域。新兴 导师将成熟,以确保未来的领导和长寿的计划。TRIO将利用现有的多机构培训基础设施和生物技术,公共卫生,转化科学, 临床研究稳健、透明的招生流程和有针对性的招聘将促进多样性,并且 严格的计划评估将允许实时改进,以满足我们KUH学员的需求。的 一体化的TRIO计划将利用跨机构的协同作用,并提供有凝聚力的方案,以培训 多学科和KUH-related研究团队的下一代领导者。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Graca Duarte Almeida-Porada其他文献

Graca Duarte Almeida-Porada的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Graca Duarte Almeida-Porada', 18)}}的其他基金

Targeted conditioning to maximize prenatal HSC engraftment for SCD
针对性调节以最大限度地提高 SCD 的产前 HSC 植入
  • 批准号:
    10654382
  • 财政年份:
    2023
  • 资助金额:
    $ 74.18万
  • 项目类别:
Using human liver tissue equivalents to optimize AAV-mediated GT and better define age-related clinical risks
使用人类肝脏组织等效物优化 AAV 介导的 GT 并更好地定义与年龄相关的临床风险
  • 批准号:
    10567919
  • 财政年份:
    2023
  • 资助金额:
    $ 74.18万
  • 项目类别:
Defining the therapeutic efficacy, tolerogenic potential, and genotoxicity of liver-targeted AAV gene therapy for hemophilia A
定义肝脏靶向 AAV 基因疗法治疗血友病 A 的疗效、耐受潜力和遗传毒性
  • 批准号:
    10704568
  • 财政年份:
    2022
  • 资助金额:
    $ 74.18万
  • 项目类别:
cGMP Manufacture Of FVIII-Expressing Placental Cells For Hemophilia A
用于治疗 A 型血友病的表达 FVIII 的胎盘细胞的 cGMP 生产
  • 批准号:
    9811291
  • 财政年份:
    2019
  • 资助金额:
    $ 74.18万
  • 项目类别:
Prenatal Cell and Gene Therapy for Hemophilia A
A 型血友病的产前细胞和基因治疗
  • 批准号:
    10014648
  • 财政年份:
    2017
  • 资助金额:
    $ 74.18万
  • 项目类别:
Prenatal Cell and Gene Therapy for Hemophilia A
A 型血友病的产前细胞和基因治疗
  • 批准号:
    9751959
  • 财政年份:
    2017
  • 资助金额:
    $ 74.18万
  • 项目类别:
Postnatal Cell-Based Therapies for Hemophilia A
A 型血友病的产后细胞疗法
  • 批准号:
    9336336
  • 财政年份:
    2016
  • 资助金额:
    $ 74.18万
  • 项目类别:
Postnatal Cell-Based Therapies for Hemophilia A
A 型血友病的产后细胞疗法
  • 批准号:
    9186030
  • 财政年份:
    2016
  • 资助金额:
    $ 74.18万
  • 项目类别:
Cord Blood Expansion Inside a Bioengineered Liver
生物工程肝脏内的脐带血扩增
  • 批准号:
    8703780
  • 财政年份:
    2013
  • 资助金额:
    $ 74.18万
  • 项目类别:
Cord Blood Expansion Inside a Bioengineered Liver
生物工程肝脏内的脐带血扩增
  • 批准号:
    8466559
  • 财政年份:
    2013
  • 资助金额:
    $ 74.18万
  • 项目类别:

相似海外基金

WELL-CALF: optimising accuracy for commercial adoption
WELL-CALF:优化商业采用的准确性
  • 批准号:
    10093543
  • 财政年份:
    2024
  • 资助金额:
    $ 74.18万
  • 项目类别:
    Collaborative R&D
Investigating the Adoption, Actual Usage, and Outcomes of Enterprise Collaboration Systems in Remote Work Settings.
调查远程工作环境中企业协作系统的采用、实际使用和结果。
  • 批准号:
    24K16436
  • 财政年份:
    2024
  • 资助金额:
    $ 74.18万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
  • 批准号:
    24K16488
  • 财政年份:
    2024
  • 资助金额:
    $ 74.18万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 74.18万
  • 项目类别:
    EU-Funded
Assessing the Coordination of Electric Vehicle Adoption on Urban Energy Transition: A Geospatial Machine Learning Framework
评估电动汽车采用对城市能源转型的协调:地理空间机器学习框架
  • 批准号:
    24K20973
  • 财政年份:
    2024
  • 资助金额:
    $ 74.18万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 74.18万
  • 项目类别:
    EU-Funded
Our focus for this project is accelerating the development and adoption of resource efficient solutions like fashion rental through technological advancement, addressing longer in use and reuse
我们该项目的重点是通过技术进步加快时装租赁等资源高效解决方案的开发和采用,解决更长的使用和重复使用问题
  • 批准号:
    10075502
  • 财政年份:
    2023
  • 资助金额:
    $ 74.18万
  • 项目类别:
    Grant for R&D
Engage2innovate – Enhancing security solution design, adoption and impact through effective engagement and social innovation (E2i)
Engage2innovate — 通过有效参与和社会创新增强安全解决方案的设计、采用和影响 (E2i)
  • 批准号:
    10089082
  • 财政年份:
    2023
  • 资助金额:
    $ 74.18万
  • 项目类别:
    EU-Funded
De-Adoption Beta-Blockers in patients with stable ischemic heart disease without REduced LV ejection fraction, ongoing Ischemia, or Arrhythmias: a randomized Trial with blinded Endpoints (ABbreviate)
在没有左心室射血分数降低、持续性缺血或心律失常的稳定型缺血性心脏病患者中停用β受体阻滞剂:一项盲法终点随机试验(ABbreviate)
  • 批准号:
    481560
  • 财政年份:
    2023
  • 资助金额:
    $ 74.18万
  • 项目类别:
    Operating Grants
Collaborative Research: SCIPE: CyberInfrastructure Professionals InnoVating and brOadening the adoption of advanced Technologies (CI PIVOT)
合作研究:SCIPE:网络基础设施专业人员创新和扩大先进技术的采用 (CI PIVOT)
  • 批准号:
    2321091
  • 财政年份:
    2023
  • 资助金额:
    $ 74.18万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了